Study of Finerenone for heart and kidney health in diabetes
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have type 2 diabetes and chronic kidney disease (specific levels of kidney function and protein in urine).
- You have been diagnosed with heart failure (New York Heart Association class II to IV) and have evidence of heart structure changes on an ultrasound.
- Your heart's pumping ability (ejection fraction) is 40% or higher, measured in the last year.
- You have elevated NT-proBNP levels (a marker of heart strain) and your potassium is not too high.
- You have not had a heart attack, stroke, or major heart procedure in the last 90 days, and you are not using certain medications that interact with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether finerenone, a pill that helps protect the kidneys and heart, can slow down kidney decline and reduce heart failure risk in people with type 2 diabetes and chronic kidney disease.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This trial tests if a medication called finerenone can improve heart structure and function in people whose heart walls are thickened. It may help people with early heart failure or related conditions like diabetes or kidney disease.
This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.